engleski

Treatment with a glucagon-like peptide-1 receptor agonist liraglutide decreases albuminuria in overweight type 2 diabetic patients

There is evidence from animal studies that treatment with glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide suppressed the progression of diabetic nephropathy with mechanisms that seem to be independent of their glucose-lowering effect. The aim of this study was to investigate effects of liraglutide therapy on renal function parameters in overweight type 2 diabetic patients. A total of 42 overweight type 2 diabetic patients with normal or mildly decreased (estimated GFR ≥ 60 mlmin-11.73 m2) renal function were included in this study and followed for 7 months. The 7- months administration of liraglutide caused a significant decrease in UAE from 19.9 (3.2- 6250.1) to 17.3 (7.5-420.1) mg/24h (p=0.04), while serum creatinine (from 71±15 to 76±19 umol/L (p=0.3)) and estimated GFR (from 90±13 to 88±18 mlmin-11.73m2 (p=0.3)) did not significantly changed. : The results of our study suggest that therapy with GLP-1 receptor agonist liraglutide may significantly reduce UAE in overweight type 2 diabetic patients.

type 2 diabetes; glucagon-like peptide-1; renal function; albuminuria

nije evidentirano